• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Christina I. Herold, MD


  • Herold CI, Anders CK.New targets for triple-negative breast cancer.Oncology (Huntingt). 2013 Sep;27(9):846-54. Review.
  • Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL.Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing.Clin Cancer Res. 2011 Sep 15;17(18):6061-70.
  • Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA.Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.Mol Cancer Res. 2011 Aug;9(8):997-1007.
  • Herold CI, Gaughan EM, Lamb CC, Tung NM.Second Primary Ipsilateral Breast Cancer With Contralateral Axillary Involvement: A Case Report and Literature Review.Clin Breast Cancer. 2011 Aug 4.
  • Herold CI, Djulbegovic B, Hozo I, Lyman GH.Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.Breast Cancer Res Treat. 2010 Jun;121(3):771-6.
  • Herold CI, Marcom PK.Primary systemic therapy in breast cancer: past lessons and new approaches.Cancer Invest. 2008 Dec;26(10):1052-9.
  • Herold CI, Blackwell KL.Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.Clin Breast Cancer. 2008 Feb;8(1):50-64. Review.
  • Herold CI, Blackwell KL.The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.Breast. 2008 Jan;17 Suppl 1:S15-24. Review.